Deerfield’s Boulevard Bio pens $1.6B deal for trispecific TCE from China’s Metis TechBio
Biotech
Summary
U.S.-based Boulevard Bio is paying $20 million upfront to China’s Metis TechBio for the global rights to a trispecific T-cell engager for autoimmune diseases.
Why It Matters
This Biotech development strengthens the region's biomanufacturing and life-sciences base. For China, it is a signal worth tracking: it shapes who supplies, who scales, and who sets the standard over the next five years.
Key Facts
- SectorBiotech
- MarketChina
- ImpactMedium (56/100)
- SignalFunding